SanBio Company Limited
Notice on Differences Between Consolidated Earnings Forecast for the Second Quarter of the Fiscal Year Ending January 2027 and Actual Results
Disclosure of the differences between the consolidated earnings forecast for the second quarter of the fiscal year ending January 2027 and actual results. Operating loss decreased due to revision of manufacturing cost recognition timing and inventory capitalization accompanying drug price listing and launch. Ordinary loss and net loss attributable to owners of the parent also improved due to foreign exchange gains from yen depreciation. For the full-year earnings forecast, no changes are expected.
Key Figures
- Operating income: △1,909 million yen
- Ordinary income: △1,730 million yen
- Net income attributable to owners of the parent (interim): △1,791 million yen
- per share interim net income: △22.95 yen
- Previous forecast (A): Operating income △2,906 million yen、Ordinary income △2,908 million yen、Net income attributable to owners of the parent △2,909 million yen、per share △37.28 yen
AI要約
Difference between earnings forecast and actual results
This release reports the differences between the consolidated earnings forecast and actual results for the second quarter cumulatively for the fiscal year ending January 2027. The operating loss underperformed due to revisions in the timing of manufacturing-related costs recognition and inventory capitalization resulting from drug price listings and launch. Ordinary loss and net loss attributable to owners of the parent improved due to the above operating loss reduction and foreign exchange gains on foreign-currency loans and receivables stemming from yen depreciation. For the full-year earnings forecast, there is no change, as manufacturing-related costs expected to be recognized in the second half are projected to be pushed to the latter half.
Outlook and cautions
Factors for the差異 include the timing of cost recognition and foreign exchange impact, with no change to the full-year forecast. However, attention should be paid to the impact of recognizing manufacturing-related costs in the second half. Future disclosures may be updated if additional differences arise.
SanBio Company Limited
Company overview · Stock price · Financial data · All IR
